SEC Form 4/A · accession 0001209191-15-056842
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Geraldine Henwood
Officer — President and CEO · Director
Period of report
Dec 17, 2014
Accepted (ET)
Jun 26, 2015 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $2.47 | Dec 17, 2014 | A | 123,500 | A | — | Dec 17, 2024 | Common Stock | 123,500 | 123,500 | D |
| Employee Stock Option (right to buy)F1,F3 | $2.47 | Dec 17, 2014 | A | 123,500 | A | — | Dec 17, 2024 | Common Stock | 123,500 | 123,500 | D |
Explanation of responses
- F1The option was granted on December 17, 2014, subject to shareholder approval at the Company's 2015 Annual Meeting of Shareholders of an amendment to increase the number of shares of common stock available for issuance under the Company's 2013 Equity Incentive Plan. Such shareholder approval was received on June 24, 2015.
- F2Upon receipt of shareholder approval, 15,437 shares subject to such options vested immediately, and the remainder will vest monthly thereafter in equal proportions until December 17, 2018.
- F3The option will vest 30% upon satisfaction of certain performance conditions, and the remainder will vest monthly thereafter in equal proportions over a three year period beginning on the date the performance conditions are satisfied.